

Lupin in promotional agreement with Exeltis for SOLOSEC

28 January 2022 | News

SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women and Trichomoniasis in adults



Lupin Pharmaceuticals and Exeltis USA announced a promotional agreement for Exeltis to promote SOLOSEC along with Exeltis' existing line of Women's Health products, further enhancing value to OBGYNs and their patients. SOLOSEC is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the US).

"The partnership will expand the reach of SOLOSEC, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC, and increase access for adult women suffering from bacterial vaginosis and adults with trichomoniasis," said Vinita Gupta, CEO, Lupin.